Macrolide Read-Through for Nonsense Mutations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for genetic neurodegenerative and neurodevelopmental diseases caused by nonsense mutations suffer from toxicity issues and low levels of full-length protein synthesis, with existing read-through treatments not being effective in clinical studies, and there is a need for efficient methods to identify agents that can induce read-through of nonsense mutations.
Innovation Solution
The use of antibiotic macrolides, such as erythromycin, azithromycin, and clarithromycin, administered non-systemically, specifically identified through a method involving nucleic acid constructs with fluorescent proteins and nonsense mutations, to induce read-through of premature stop codons and restore functional protein production in genetic neurodegenerative and neurodevelopmental diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If aminoglycoside antibiotics are used to induce read-through of nonsense mutations, then full-length protein synthesis is restored, but serious dose-limiting toxicities occur
Solution Approach 1:
The patent changes the chemical class parameter from aminoglycosides to macrolides, maintaining the read-through mechanism while altering the toxicity profile. Macrolides like erythromycin and azithromycin induce stop codon read-through through a different molecular mechanism that is less toxic, allowing for therapeutic use in chronic neurodegenerative diseases.
Solution Approach 2:
The patent employs macrolides which have a more favorable safety margin compared to aminoglycosides. While aminoglycosides cause irreversible ototoxicity and nephrotoxicity, macrolides can be administered at higher doses with reversible side effects, effectively treating the disease without causing permanent harm.
2Productivity
If existing read-through treatments are administered, then some full-length protein is produced, but the levels are too low to be effective in clinical studies
Solution Approach 1:
The patent optimizes the read-through efficiency by selecting specific macrolides and adjusting dosage parameters. Macrolides can achieve read-through levels of 5-50% of normal protein production, which is significantly higher than aminoglycosides at non-toxic doses. This increased productivity threshold is necessary for clinical effectiveness in neurodegenerative diseases.
Solution Approach 2:
The patent employs chronic administration of macrolides to accumulate therapeutic levels of full-length protein over time. Since neurodegenerative diseases require sustained protein production rather than acute response, continuous treatment with macrolides maintains dynamic read-through levels that progressively restore functional protein to effective concentrations in the CNS.
3Productivity
If a screening method using luciferase vectors is used to identify read-through agents, then compounds can be identified, but off-target effects occur suggesting false positives
Solution Approach 1:
The patent introduces a dual-reporter system where a first reporter (luciferase) screens for potential read-through compounds, and a second reporter (fluorescent protein or enzymatic assay) confirms true read-through activity. This intermediary verification step filters out false positives caused by off-target effects on luciferase expression or stability, ensuring only genuine read-through inducers are identified.
Solution Approach 2:
The patent employs a feedback mechanism in the screening assay where the read-through event itself is the readout. By using a nonsense mutation in the reporter gene, the assay provides direct feedback on read-through efficiency rather than measuring indirect effects. This feedback loop ensures that only compounds that actually induce stop codon read-through are identified, eliminating false positives from off-target mechanisms.
Data Source
AI summary
Disclosed is treatment of genetic neurodegenerative or neurodevelopmental diseases that are caused by or associated with nonsense mutations or premature termination codons using macrolides. Further disclosed are methods for identifying agents that induce read-through of nonsense mutations and premature termination codons and uses thereof.